Related Experiment Video

Updated: May 25, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy

Nicolò Rigamonti1, Matteo Bellone

  • 1Cellular Immunology Unit, Program of Immunology, Gene Therapy and Bio-Immunotherapy of Cancer, San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy. rigamonti.nicolo@hsr.it

Cancer Immunology, Immunotherapy : CII
|February 15, 2012
PubMed

Insights

Prostate cancer immunotherapy shows modest results because tumors promote inflammation and evade immune surveillance. New strategies and mouse models are crucial for advancing prostate cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Cancer immunotherapy

Background:

  • Recent FDA approval of the first prostate cancer therapeutic vaccine has increased interest in cancer immunology and immunotherapy.
  • Clinical outcomes for prostate cancer immunotherapy remain modest, suggesting underlying challenges in treatment efficacy.

Purpose of the Study:

  • To review the interactions between prostate tumors and the immune system.
  • To explain how prostate cancer evades immune surveillance through immunosuppressive mechanisms.
  • To discuss strategies for overcoming cancer immune evasion and the role of murine models.

Main Methods:

  • Review of existing literature on prostate cancer-immune system interactions.
  • Analysis of tumor-induced inflammation and immunosuppressive mechanisms.
  • Discussion of experimental and clinical strategies for cancer immunotherapy.

Main Results:

  • Prostate tumors can manipulate inflammation to promote their growth and escape immune detection.
  • Malignancies employ various immunosuppressive mechanisms to evade the host immune system.
  • The transgenic adenocarcinoma of the mouse prostate (TRAMP) model is highlighted as valuable for research.

Conclusions:

  • Understanding tumor-immune interactions is key to improving prostate cancer immunotherapy.
  • Counteracting tumor-induced immunosuppression is essential for successful treatment.
  • Appropriate preclinical models are vital for developing and testing novel immunotherapies for prostate cancer.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...